The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 27, 2025
Filed:
Feb. 19, 2021
Replication-competent attenuated chimeric vsv vectors encoding immunogenic sars-cov-2 spike proteins
International Aids Vaccine Initiative Inc., New York, NY (US);
Merck Sharp & Dohme Llc, Rahway, NJ (US);
Christopher Lee Parks, Boonton, NJ (US);
Maoli Yuan, Brooklyn, NY (US);
Mark Feinberg, New York, NY (US);
Amy Espeseth, Chalfont, PA (US);
Andrew J. Bett, West Point, PA (US);
INTERNATIONAL AIDS VACCINE INITIATIVE INC., New York, NY (US);
MERCK SHARP & DOHME LLC, Rahway, NJ (US);
Abstract
The present disclosure provides Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) vaccines, recombinant vesicular stomatitis virus (VSV) vectors encoding the SARS-CoV-2 spike (S) protein or an immunogenic variant thereof, recombinant replicable VSV particles having a SARS-CoV-2 S protein or an immunogenic variant thereof on the surface of the particles, and immunogenic recombinant proteins comprising a SARS-CoV-2 S protein or a variant thereof. Immunogenic compositions comprising the SARS-CoV-2 vaccines, the recombinant VSV vectors, the recombinant replicable VSV particles and/or the immunogenic recombinant proteins may be used for inducing an immune response to the SARS-CoV-2, preventing infection by the SARS-CoV-2, vaccinating against the SARS-CoV-2 and/or producing adaptive mutants of the recombinant replicable VSV particles.